<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cutaneous xanthomas</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cutaneous xanthomas</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cutaneous xanthomas</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karolyn Wanat, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Megan H Noe, MD, MPH, MSCE</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mason W Freeman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H597369390"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Xanthomas are localized lipid deposits within organs that may manifest as papules, plaques, or nodules in skin. The clinical variants of cutaneous xanthomas include:</p><p class="bulletIndent1"><span class="glyph">●</span>Eruptive xanthomas (<a class="graphic graphic_picture graphicRef104992 graphicRef104993 graphicRef104994" href="/d/graphic/104992.html" rel="external">picture 1A-C</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Tuberous xanthomas (<a class="graphic graphic_picture graphicRef104995 graphicRef104996 graphicRef72875" href="/d/graphic/104995.html" rel="external">picture 2A-C</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Tendinous xanthomas (<a class="graphic graphic_picture graphicRef104997" href="/d/graphic/104997.html" rel="external">picture 3</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Plane xanthomas (including xanthelasma) (<a class="graphic graphic_picture graphicRef102780 graphicRef102779 graphicRef104998" href="/d/graphic/102780.html" rel="external">picture 4A-C</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Verruciform xanthomas (<a class="graphic graphic_picture graphicRef105689" href="/d/graphic/105689.html" rel="external">picture 5</a>)</p><p></p><p>Cutaneous xanthomas can be idiopathic or a sign of an inherited abnormality of lipoprotein metabolism (primary dyslipidemia), hyperlipidemia secondary to systemic disease or medication, or hematologic disease. The subtype of xanthoma provides a clue to the underlying abnormality. Accurate diagnosis of xanthomas is important because it can lead to the identification and treatment of underlying disease (<a class="graphic graphic_algorithm graphicRef140031" href="/d/graphic/140031.html" rel="external">algorithm 1</a>).</p><p>The clinical features, diagnosis, and management of patients with cutaneous xanthomas will be reviewed here. The causes and management of lipid disorders are discussed separately. (See  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia"</a> and  <a class="medical medical_review" href="/d/html/4568.html" rel="external">"Secondary causes of dyslipidemia"</a> and  <a class="medical medical_review" href="/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management"</a>.)</p><p class="headingAnchor" id="H597369396"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Epidemiologic data on cutaneous xanthomas are limited. With the exception of xanthelasma, the most common subtype, cutaneous xanthomas are uncommon. Xanthelasma occur both in the presence and absence of hyperlipidemia with estimates of prevalence in the general population ranging from less than 1 to 4 percent [<a href="#rid1">1</a>]. Tuberous, tuberoeruptive, tendinous, and nonxanthelasma plane xanthomas typically occur in association with inherited or acquired dyslipidemia or hematologic disease [<a href="#rid2">2,3</a>]. (See <a class="local">'Clinical variants'</a> below.)</p><p>Cutaneous xanthomas most often present in adulthood. Xanthomas associated with familial hypercholesterolemia are an exception; xanthomas in patients with this disorder often begin to develop prior to the age of 10 years. Cutaneous xanthomas occur in both males and females. There does not appear to be a clear sex predilection.</p><p class="headingAnchor" id="H597369402"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Cutaneous xanthomas represent deposition of lipid and associated inflammation in the skin. The pathogenic mechanisms that lead to cutaneous xanthomas are not fully understood and may differ based upon the etiology and type of xanthoma.</p><p>For xanthomas occurring in association with hyperlipidemia, it is hypothesized that when serum levels of lipoproteins are substantially elevated, extravasation of lipoproteins through dermal capillary blood vessels with subsequent engulfment by macrophages leads to the lipid-laden cells found in xanthomas, which has been demonstrated using electron microscopy [<a href="#rid4">4,5</a>]. Earlier studies suggested the cutaneous lipid accumulation was a result of de novo lipid synthesis [<a href="#rid6">6,7</a>].</p><p>Primary or secondary hyperlipidemic states can lead to xanthoma formation. Primary hyperlipidemia results from genetic defects in receptors, receptor ligands, or enzymes involved in lipid metabolism. Causes of secondary hyperlipidemia include underlying disease states and medications. Examples of diseases and physiologic states associated with hyperlipidemia include obesity, diabetes mellitus, hypothyroidism, nephrotic syndrome, cholestasis, and pregnancy [<a href="#rid8">8-13</a>]. Examples of medications that may lead to hyperlipidemia (often hypertriglyceridemia) include estrogens, <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, oral retinoids, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9448" href="/d/drug information/9448.html" rel="external">nilotinib</a>, and protease inhibitors [<a href="#rid14">14-18</a>]. (See  <a class="medical medical_review" href="/d/html/4568.html" rel="external">"Secondary causes of dyslipidemia"</a> and  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia"</a> and  <a class="medical medical_review" href="/d/html/107507.html" rel="external">"Familial hypercholesterolemia in adults: Overview"</a> and  <a class="medical medical_review" href="/d/html/132419.html" rel="external">"Hypertriglyceridemia in adults: Approach to evaluation", section on 'Symptoms and signs'</a>.)</p><p>Some plane xanthomas occur in the absence of dyslipidemia. Diffuse normolipemic plane xanthoma, a rare subtype of plane xanthoma, often develops in association with monoclonal gammopathy, multiple myeloma, and other hematologic diseases. Immune complex formation between antibodies and lipoproteins leading to lipid accumulation within macrophages is a proposed mechanism for xanthoma formation in the setting of monoclonal gammopathy [<a href="#rid19">19</a>]. The mechanism of xanthelasma (periorbital plane xanthoma) formation in patients without dyslipidemia is unclear. (See <a class="local">'Plane xanthomas'</a> below.)</p><p>Verruciform xanthomas are not associated with hyperlipidemia or underlying disease. Verruciform xanthomas may represent an immune reaction to local trauma or inflammation [<a href="#rid20">20</a>]. (See <a class="local">'Verruciform xanthomas'</a> below.)</p><p class="headingAnchor" id="H597369408"><span class="h1">CLINICAL VARIANTS</span><span class="headingEndMark"> — </span>The clinical variants of cutaneous xanthoma include eruptive xanthomas, tuberous and tuberoeruptive xanthomas, tendinous xanthomas, plane xanthomas (including xanthelasma), and verruciform xanthomas. Most xanthomas present as erythematous to yellow papules, plaques, or nodules representative of lipid deposition in the skin.</p><p>The characteristic histologic feature of cutaneous xanthomas is lipid-laden macrophages, also known as "foam cells." The number of foam cells and the presence of associated findings, such as inflammatory cells, extracellular lipid deposition, and fibrosis vary with the type and age of the xanthoma. Eruptive xanthomas often have prominent extracellular lipid deposition, and tuberous and tendinous xanthomas often have large foam cells with associated fibrosis [<a href="#rid2">2,21</a>].</p><p class="headingAnchor" id="H714674399"><span class="h2">Eruptive xanthomas</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Eruptive xanthomas are 1 to 5 mm erythematous to yellow papules that appear in crops and have an abrupt onset (<a class="graphic graphic_picture graphicRef104992 graphicRef104993 graphicRef104994" href="/d/graphic/104992.html" rel="external">picture 1A-C</a>). The most common sites of involvement are the extensor surfaces of the extremities and buttocks. Koebnerization (the appearance of eruptive xanthomas at sites of skin trauma) can occur.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated disorders</strong> – Eruptive xanthomas are highly suggestive of hypertriglyceridemia and are often associated with serum triglyceride levels exceeding 1500 to 2000 mg/dL. Lipid disorders that may result in eruptive xanthomas are those in which very low density lipoprotein (VLDL) levels, chylomicron levels, or both are dramatically increased (<a class="graphic graphic_table graphicRef105471" href="/d/graphic/105471.html" rel="external">table 1</a>). Occasionally, eruptive xanthomas are the initial sign of diabetes [<a href="#rid22">22,23</a>]. Eruptive xanthomas have also occurred in association with hypertriglyceridemia-induced pancreatitis [<a href="#rid24">24</a>]. (See  <a class="medical medical_review" href="/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – Eruptive xanthomas demonstrate foam cells, a mixed inflammatory cell infiltrate with lymphocytes, neutrophils, and histiocytes, and extracellular lipid deposits. Foam cells may be few in number in early eruptive xanthomas. </p><p></p><p class="headingAnchor" id="H714674409"><span class="h2">Tuberous xanthomas</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Tuberous xanthomas are yellow-orange or erythematous papules or nodules located over joints or extensor surfaces of the extremities, especially the elbows and knees (<a class="graphic graphic_picture graphicRef104995 graphicRef104996 graphicRef72875" href="/d/graphic/104995.html" rel="external">picture 2A-C</a>). They may be solitary or grouped and they can reach sizes up to 3 cm. The term "tuberoeruptive xanthomas" may be used to refer to papular lesions. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated disorders</strong> – Tuberous xanthomas occur in hypercholesterolemic states, such as with familial hypercholesterolemia (low-density lipoprotein [LDL] levels elevated) or when intermediate density lipoprotein levels are high (familial dysbetalipoproteinemia), in which case the serum cholesterol and triglyceride levels may be similarly increased (eg, each is approximately 400 mg/dL) (<a class="graphic graphic_table graphicRef105471" href="/d/graphic/105471.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – Tuberous xanthomas demonstrate abundant foam cells (<a class="graphic graphic_picture graphicRef105000" href="/d/graphic/105000.html" rel="external">picture 6</a>). A mild inflammatory infiltrate may also be present. Older tuberous xanthomas may exhibit increased fibroblasts and collagen deposition.</p><p></p><p class="headingAnchor" id="H714674425"><span class="h2">Tendinous xanthomas</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Tendinous xanthomas are smooth, firm but mobile, skin-colored nodules (<a class="graphic graphic_picture graphicRef104997" href="/d/graphic/104997.html" rel="external">picture 3</a>). They appear over tendons or ligaments, most commonly the Achilles tendon. Tendinous xanthomas are incorporated into the tendon and will move as the tendon passes back and forth with joint extension and flexion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated disorders</strong> – Tendinous xanthomas commonly occur in genetic hypercholesterolemic syndromes due to elevated LDL levels, either caused by LDL receptor mutations (familial hypercholesterolemia) or defects in the LDL apoprotein, apolipoprotein B-100 (familial defective apo B-100). Tendinous xanthomas also can develop in cerebrotendinous xanthomatosis, a rare autosomal recessive lipid storage disease that leads to the accumulation of cholesterol and cholestanol in tissues and results in neurologic dysfunction [<a href="#rid25">25</a>]. Patients with sitosterolemia, a rare inherited sterol storage disease, may also develop tendinous xanthomas [<a href="#rid26">26</a>]. (See  <a class="medical medical_review" href="/d/html/1692.html" rel="external">"Cerebrotendinous xanthomatosis"</a> and  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – The histopathology of tendinous xanthomas is similar to tuberous xanthomas.</p><p></p><p class="headingAnchor" id="H714674442"><span class="h2">Plane xanthomas</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Plane xanthomas are soft yellow thin plaques that are found most commonly around the eyelids (xanthelasma), neck, trunk, shoulders, and axillae (<a class="graphic graphic_picture graphicRef102780 graphicRef102779 graphicRef104998" href="/d/graphic/102780.html" rel="external">picture 4A-C</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated disorders</strong> – Plane xanthomas can occur in both the presence and absence of primary or secondary hyperlipidemia. Xanthoma striatum palmare, plane xanthomas within the creases of the palms, are pathognomonic for familial dysbetalipoproteinemia (<a class="graphic graphic_picture graphicRef104999" href="/d/graphic/104999.html" rel="external">picture 7</a>). Interdigital xanthomas, especially between the thumb and index finger, are pathognomonic for homozygous familial hypercholesterolemia [<a href="#rid27">27,28</a>]. Plane xanthomas also can occur in the setting of cholestasis-related hypercholesterolemia in primary biliary cholangitis or in biliary atresia seen in Alagille syndrome [<a href="#rid29">29-31</a>]. These patients often develop xanthomatous plaques on the hands and feet. (See  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia"</a> and  <a class="medical medical_review" href="/d/html/3602.html" rel="external">"Hypercholesterolemia in primary biliary cholangitis (primary biliary cirrhosis)"</a> and  <a class="medical medical_review" href="/d/html/14369.html" rel="external">"Biliary atresia"</a>.)</p><p></p><p class="bulletIndent1">The relationship between xanthelasma and dyslipidemia has been controversial. A systematic review and meta-analysis of 15 case-control studies that assessed serum lipid levels in individuals with xanthelasma found higher serum levels of total cholesterol (standard mean difference [SMD] 0.612, 95% CI 0.376-0.848) and LDLs (SMD 0.587, 95% CI 0.339-0.836) in patients with xanthelasma than in control patients, supporting an increased risk for dyslipidemia in this population [<a href="#rid32">32</a>]. Patients with xanthelasma also had higher levels of apolipoprotein B (a risk marker of atherosclerosis) and higher carotid intima-media thickness (a surrogate marker of atherosclerosis), suggesting increased risk for atherosclerotic disease. Significant differences in levels of high-density lipoproteins (HDLs), VLDLs, and triglycerides were not detected between the populations. (See <a class="local">'Laboratory evaluation'</a> below.)</p><p></p><p class="bulletIndent1">Diffuse normolipemic plane xanthoma is a rare subtype of plane xanthoma characterized by a symmetrical eruption of plane xanthomas on the face, neck, and upper trunk in the absence of hyperlipidemia. These xanthomas most frequently develop in patients with hematologic disorders, such as monoclonal gammopathy, multiple myeloma, chronic myelomonocytic leukemia, myelodysplastic syndrome, and lymphoproliferative disorders (eg, B cell lymphoma, Castleman disease) [<a href="#rid33">33</a>]. The xanthomas may precede the diagnosis of hematologic disease [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – Plane xanthomas exhibit aggregates of foam cells in the upper dermis. Inflammatory cells may be few or absent. Biopsies of xanthelasma also demonstrate small vellus hairs and superficial, thin muscles, consistent with the eyelid location (<a class="graphic graphic_picture graphicRef105005" href="/d/graphic/105005.html" rel="external">picture 8</a>).</p><p></p><p class="headingAnchor" id="H714674478"><span class="h2">Verruciform xanthomas</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Verruciform xanthomas are solitary, erythematous, flat or verrucous papules that most commonly develop in the oral cavity or on anogenital skin (<a class="graphic graphic_picture graphicRef105689" href="/d/graphic/105689.html" rel="external">picture 5</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated disorders </strong>–<strong> </strong>Verruciform xanthomas can develop independently [<a href="#rid35">35</a>] or in association with a variety of disorders, including recessive dystrophic epidermolysis bullosa [<a href="#rid36">36</a>], congenital hemidysplasia with ichthyosiform erythroderma and limb defects (CHILD) syndrome [<a href="#rid37">37</a>], chronic lymphedema [<a href="#rid38">38-40</a>], graft versus host disease [<a href="#rid41">41,42</a>], or oral lichen planus [<a href="#rid43">43,44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology</strong> – Verruciform xanthomas have a characteristic histopathologic appearance, demonstrating a papillomatous epidermis with cup-shaped invaginations of parakeratosis (<a class="graphic graphic_picture graphicRef105001 graphicRef105002" href="/d/graphic/105001.html" rel="external">picture 9A-B</a>). There are neutrophils and foam cells in the dermal papillae [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H597369414"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of cutaneous xanthomas involves determining the type of xanthoma and the underlying cause through the patient history, physical examination, and relevant laboratory studies. Often, the classic yellow or yellow-red color and distribution of eruptive, tuberous, and plane xanthomas (eg, eyelids in xanthelasma) enables a presumptive diagnosis. Correlation of the clinical and pathologic findings confirms the diagnosis.</p><p class="headingAnchor" id="H714674486"><span class="h2">Clinical assessment</span><span class="headingEndMark"> — </span>The patient history should include an assessment for risk factors for xanthoma development. We assess patients for:</p><p class="bulletIndent1"><span class="glyph">●</span>Underlying diseases (eg, diabetes, thyroid disease, nephrotic syndrome, hematologic disease)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medications that may cause hyperlipidemia (eg, estrogens, <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, oral retinoids, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9448" href="/d/drug information/9448.html" rel="external">nilotinib</a>, and protease inhibitors)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history of primary lipid disorders or diseases associated with hyperlipidemia </p><p></p><p>The physical examination should include an assessment of the morphology and location of the xanthoma(s). Physical findings that suggest particular variants include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eruptive xanthomas</strong> – Multiple small, yellow to yellow-red papules on the buttocks or extensor extremities (<a class="graphic graphic_picture graphicRef104992 graphicRef104993 graphicRef104994" href="/d/graphic/104992.html" rel="external">picture 1A-C</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tuberous xanthomas</strong> – Yellow-orange or erythematous papules or nodules on the extensor extremities or joints (<a class="graphic graphic_picture graphicRef104995 graphicRef104996 graphicRef72875" href="/d/graphic/104995.html" rel="external">picture 2A-C</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tendinous xanthomas</strong> – Skin-colored, mobile nodules over tendons or ligaments (<a class="graphic graphic_picture graphicRef104997" href="/d/graphic/104997.html" rel="external">picture 3</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Plane xanthomas</strong> – Yellow, thin plaques on the eyelids (xanthelasma), neck, trunk, shoulders, or axillae (<a class="graphic graphic_picture graphicRef102780 graphicRef102779 graphicRef104998" href="/d/graphic/102780.html" rel="external">picture 4A-C</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Verruciform xanthomas</strong> – Verrucous papules in the oral cavity or on anogenital skin (<a class="graphic graphic_picture graphicRef105689" href="/d/graphic/105689.html" rel="external">picture 5</a>)</p><p></p><p class="headingAnchor" id="H714674492"><span class="h2">Biopsy</span><span class="headingEndMark"> — </span>A shave, punch, or excisional skin biopsy can identify histologic features consistent with a cutaneous xanthoma and can confirm the diagnosis when correlated with the clinical findings. (See <a class="local">'Clinical variants'</a> above and  <a class="medical medical_review" href="/d/html/5577.html" rel="external">"Skin biopsy techniques"</a>.)</p><p class="headingAnchor" id="H714674498"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>A fasting lipid panel to evaluate for dyslipidemia should be performed in all patients with xanthomas, with the exception of patients with verruciform xanthomas (<a class="graphic graphic_algorithm graphicRef140031" href="/d/graphic/140031.html" rel="external">algorithm 1</a>). Verruciform xanthomas are not associated with hyperlipidemia. (See <a class="local">'Verruciform xanthomas'</a> above.)</p><p>Patients with hyperlipidemia should receive further evaluation to identify the cause of dyslipidemia. Patients with eruptive or plane xanthomas and hyperlipidemia warrant evaluations for causes of secondary hyperlipidemia, such as diabetes, thyroid disease, liver disease, or renal disease. We typically begin the evaluation of these patients by obtaining a fasting glucose level, hemoglobin A1C, liver function tests, thyroid-stimulating hormone, and renal function tests, depending on patient history and review of symptoms. If a cause of secondary hyperlipidemia does not become evident in a patient with eruptive or plane xanthomas, the patient should be evaluated for primary (inherited) dyslipidemia. Patients with tendinous or tuberous xanthomas automatically should be evaluated for an inherited dyslipidemia.</p><p>While children with sitosterolemia can present with normolipemic xanthomas, in adults without evidence of dyslipidemia, a diagnosis of eruptive, tuberous, or tendinous xanthomas should be reconsidered given the strong association of these subtypes with dyslipidemia. (See  <a class="medical medical_review" href="/d/html/4567.html" rel="external">"Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia"</a> and  <a class="medical medical_review" href="/d/html/4568.html" rel="external">"Secondary causes of dyslipidemia"</a> and  <a class="medical medical_review" href="/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management"</a> and  <a class="medical medical_review" href="/d/html/121831.html" rel="external">"Familial hypercholesterolemia in children", section on 'Differential diagnosis'</a>.)</p><p>Patients with plane xanthomas can be normolipidemic. Because of the association of diffuse normolipemic plane xanthomas with hematologic disease, these patients should be evaluated for an associated hematologic disease. Reasonable initial laboratory studies include:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count</p><p class="bulletIndent1"><span class="glyph">●</span>Serum protein electrophoresis and serum immunofixation </p><p class="bulletIndent1"><span class="glyph">●</span>Serum free light chain assay </p><p></p><p class="headingAnchor" id="H597369420"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of xanthomas depends on the clinical variant. When necessary, a skin biopsy can differentiate cutaneous xanthomas from other disorders.</p><p>Xanthelasma, the most common type cutaneous xanthoma, should be distinguished from other causes of persistent periocular papules. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sebaceous hyperplasia</strong> – Sebaceous hyperplasia presents as single or multiple, yellow-orange, 2 to 6 mm, lobulated papules with a central dell (<a class="graphic graphic_picture graphicRef98390 graphicRef98389" href="/d/graphic/98390.html" rel="external">picture 10A-B</a>). The face is the most common site of involvement. (See  <a class="medical medical_review" href="/d/html/16910.html" rel="external">"Cutaneous adnexal tumors", section on 'Sebaceous hyperplasia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Juvenile xanthogranuloma</strong> – Juvenile xanthogranuloma classically presents as reddish or yellowish skin papules or nodules on the head, neck, or upper trunk (<a class="graphic graphic_picture graphicRef69122 graphicRef75895" href="/d/graphic/69122.html" rel="external">picture 11A-B</a>). Unlike xanthelasma, juvenile xanthogranuloma most commonly occurs in young children. (See  <a class="medical medical_review" href="/d/html/13729.html" rel="external">"Juvenile xanthogranuloma (JXG)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Syringoma</strong> – Syringomas usually present as firm, grouped papules on periorbital skin (<a class="graphic graphic_picture graphicRef98458" href="/d/graphic/98458.html" rel="external">picture 12</a>). Syringomas are skin-colored and lack the yellow color typical of xanthelasma. (See  <a class="medical medical_review" href="/d/html/16910.html" rel="external">"Cutaneous adnexal tumors", section on 'Syringoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nodular basal cell carcinoma</strong> – Nodular basal cell carcinoma commonly occurs on the face, typically manifesting as a pearly papule with arborizing telangiectasias (<a class="graphic graphic_picture graphicRef65704" href="/d/graphic/65704.html" rel="external">picture 13</a>). Basal cell carcinomas lack the yellow hue of xanthelasma. (See  <a class="medical medical_review" href="/d/html/5335.html" rel="external">"Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p>Plane xanthomas should be distinguished from necrobiotic xanthogranuloma (NXG). NXG is a non-Langerhans histiocytosis that is often associated with monoclonal gammopathy. Patients with NXG typically develop red-brown, violaceous, or yellowish cutaneous papules, plaques, or nodules on periorbital skin or other sites (<a class="graphic graphic_picture graphicRef102781 graphicRef102782" href="/d/graphic/102781.html" rel="external">picture 14A-B</a>). (See  <a class="medical medical_review" href="/d/html/89275.html" rel="external">"Necrobiotic xanthogranuloma"</a>.)</p><p>The multiple papules of eruptive xanthomas should be distinguished from generalized granuloma annulare and xanthoma disseminatum. Generalized granuloma annulare manifests with widespread skin-colored to erythematous papules or plaques on the trunk and extremities (<a class="graphic graphic_picture graphicRef64223 graphicRef53172" href="/d/graphic/64223.html" rel="external">picture 15A-B</a>). Xanthoma disseminatum is a form of non-Langerhans cell histiocytosis characterized by red-brown papules and plaques in the flexural areas of the trunk or proximal extremities [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/d/html/13705.html" rel="external">"Granuloma annulare: Epidemiology, clinical manifestations, and diagnosis", section on 'Generalized granuloma annulare'</a>.)</p><p>Tendinous xanthomas and tuberous xanthomas may resemble other nodular eruptions with predilections for sites over joints or tendons. Examples include rheumatoid nodules (<a class="graphic graphic_picture graphicRef74194" href="/d/graphic/74194.html" rel="external">picture 16</a>), gouty tophi (<a class="graphic graphic_picture graphicRef74050" href="/d/graphic/74050.html" rel="external">picture 17</a>), subcutaneous granuloma annulare (<a class="graphic graphic_picture graphicRef65614" href="/d/graphic/65614.html" rel="external">picture 18</a>), and erythema elevatum diutinum (<a class="graphic graphic_picture graphicRef101252 graphicRef67776" href="/d/graphic/101252.html" rel="external">picture 19A-B</a>). Knowledge of underlying medical conditions is useful for narrowing the differential diagnosis.</p><p>Verrucous xanthomas on the oral and genital mucosa may be clinically confused with condylomata, oral papillomas, verrucous carcinoma, and squamous cell carcinoma.</p><p class="headingAnchor" id="H597369426"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Cutaneous xanthomas are not life-threatening and are usually asymptomatic. Therefore, treatment specifically for cutaneous xanthomas is not mandatory, although it is often desired for cosmetic reasons.</p><p>However, pharmacologic treatment of dyslipidemia is usually indicated and often leads to concomitant improvement in eruptive, tuberous, tendinous, and plane xanthomas caused by hyperlipidemia [<a href="#rid47">47-49</a>]. Eruptive xanthomas typically resolve within several weeks when triglyceride levels are reduced. Tuberous and tendinous xanthomas are slower to regress during treatment of dyslipidemia. (See  <a class="medical medical_review" href="/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management", section on 'Treatment goals'</a> and  <a class="medical medical_review" href="/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p>Different approaches are necessary for the treatment of xanthomas that are not associated with dyslipidemia. Normolipidemic patients with xanthelasma who desire treatment are primarily treated with surgical excision or destructive interventions. Traditionally, surgical excision has been used, with good cosmetic results [<a href="#rid50">50</a>]. Other effective treatment methods include destruction of xanthelasma with cryotherapy; 70% <a class="drug drug_general" data-topicid="10296" href="/d/drug information/10296.html" rel="external">trichloroacetic acid</a> chemical peels; intralesional <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>; and treatment with carbon dioxide (CO<sub>2</sub>), erbium-doped yttrium aluminium garnet (Er:YAG), or Q-switched neodymium-doped yttrium aluminium garnet (Nd:YAG) lasers [<a href="#rid51">51-56</a>]. Of note, surgical and destructive techniques do not prevent recurrences or new xanthelasma.</p><p>Although small normolipemic plane xanthomas, such as xanthelasma, are amenable to surgical or destructive therapies, such treatment is often impractical for patients with more extensive skin involvement, leaving the best approach to treatment of these lesions unclear. A split-face, randomized, controlled trial suggested that fractional CO<sub>2</sub> laser therapy was superior to Er:YAG laser therapy, with more patients experiencing clinical improvement with fewer treatments on the side treated with the fractional CO<sub>2</sub> laser [<a href="#rid57">57</a>].</p><p>Diffuse normolipemic plane xanthomas that occur in association with hematologic disease tend to be persistent. However, remission of the hematologic disease has been associated with improvement of the skin lesions [<a href="#rid19">19</a>].</p><p>Verruciform xanthomas are generally treated with surgical excision [<a href="#rid58">58-60</a>]. In addition, case reports have described resolution of a large verruciform xanthoma on the vulva with topical <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> and successful treatment of a scrotal verruciform xanthoma with shave debulking followed by fractionated CO<sub>2</sub> laser therapy [<a href="#rid58">58,61</a>].</p><p class="headingAnchor" id="H714677133"><span class="h1">PROGNOSIS AND FOLLOW-UP</span><span class="headingEndMark"> — </span>Without treatment, xanthomas typically persist. Patients with hyperlipidemia-associated xanthomas require clinical follow up for morbidities associated with hyperlipidemia and underlying causes of hyperlipidemia. In addition, patients with diffuse plane xanthomas who lack evidence for hematologic disease at the time of diagnosis require long-term follow up for the development of hematologic disease [<a href="#rid34">34</a>].</p><p>There is uncertainty about the prognostic implications of xanthelasma in the absence of hyperlipidemia. A study of 20 normolipidemic patients with xanthelasma, 20 hyperlipidemic patients with xanthelasma, and 40 normolipidemic participants without xanthelasma found higher (albeit normal) levels of total cholesterol and triglycerides in normolipidemic patients with xanthelasma than control patients [<a href="#rid62">62</a>]. Carotid artery intima-media thickness, a marker for atherosclerosis, also was higher in normolipidemic patients with xanthelasma than controls. These findings suggest that xanthelasma is associated with increased risk for atherosclerosis, independent of lipid concentrations. Larger studies are necessary to confirm this conclusion.</p><p class="headingAnchor" id="H597369444"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Xanthomas are localized deposits of lipids within the organs that occur most commonly in the setting of an underlying lipid abnormality. The major subtypes of cutaneous xanthomas are eruptive xanthoma, tuberous xanthoma, tendinous xanthoma, plane xanthoma, and verruciform xanthoma. (See <a class="local">'Clinical variants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical variants</strong> – The clinical variants of cutaneous xanthomas have varying clinical features and disease associations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Eruptive xanthomas</strong> – Eruptive xanthomas manifest as crops of erythematous to yellow 1 to 5 mm papules that usually appear on the extensor surfaces of the extremities and buttocks (<a class="graphic graphic_picture graphicRef104992 graphicRef104993 graphicRef104994" href="/d/graphic/104992.html" rel="external">picture 1A-C</a>). Eruptive xanthomas occur in the setting of severe hypertriglyceridemia. (See <a class="local">'Eruptive xanthomas'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tuberous xanthomas</strong> – Tuberous xanthomas are yellow-orange or erythematous papules or nodules that usually appear on skin over joints or extensor surfaces of the extremities (<a class="graphic graphic_picture graphicRef104995 graphicRef104996 graphicRef72875" href="/d/graphic/104995.html" rel="external">picture 2A-C</a>). Tuberous xanthomas occur in the setting of hypercholesterolemia. (See <a class="local">'Tuberous xanthomas'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Tendinous xanthomas</strong> – Tendinous xanthomas are smooth, skin-colored nodules found over tendons or ligaments (<a class="graphic graphic_picture graphicRef104997" href="/d/graphic/104997.html" rel="external">picture 3</a>). Tendinous xanthomas most commonly occur in familial hyperlipidemia syndromes with elevated low-density lipoprotein (LDL) or familial defective apolipoprotein B-100. (See <a class="local">'Tendinous xanthomas'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Plane xanthomas</strong> – Plane xanthomas are soft, yellow plaques found around the eyelids (xanthelasma), neck, trunk shoulders or axillae (<a class="graphic graphic_picture graphicRef102780 graphicRef102779 graphicRef104998" href="/d/graphic/102780.html" rel="external">picture 4A-C</a>). Plane xanthomas may occur in the presence or absence of hyperlipidemia. Rarely, plane xanthomas are associated with monoclonal gammopathies, multiple myeloma, or other hematologic disease. (See <a class="local">'Plane xanthomas'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Verruciform xanthomas</strong> – Verruciform xanthomas are flat or verrucous papules that most commonly appear on the oral mucosa or anogenital skin. Verruciform xanthomas are not associated with dyslipidemia. (See <a class="local">'Verruciform xanthomas'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A diagnosis of cutaneous xanthomas can be suspected based upon the physical findings and confirmed with a skin biopsy. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional evaluation</strong> – All patients with cutaneous xanthomas, with the exception of patients with verruciform xanthomas, should be evaluated for the presence of hyperlipidemia (<a class="graphic graphic_algorithm graphicRef140031" href="/d/graphic/140031.html" rel="external">algorithm 1</a>). Hyperlipidemia in patients with eruptive or plane xanthomas warrants an evaluation for causes of secondary hyperlipidemia. Normolipidemic patients with diffuse plane xanthomas require evaluation for underlying hematologic disease. (See <a class="local">'Laboratory evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Cutaneous xanthomas associated with hyperlipidemia often improve with treatment of the underlying lipid abnormality. Surgical and destructive treatments are the primary therapeutic options for xanthelasma in normolipidemic patients and for verruciform xanthomas. (See <a class="local">'Treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Zak A, Zeman M, Slaby A, Vecka M. Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014; 158:181.</a></li><li><a class="nounderline abstract_t">Love JR, Dubin HV. Xanthomas and lipoproteins. Cutis 1978; 21:801.</a></li><li><a class="nounderline abstract_t">Cruz PD Jr, East C, Bergstresser PR. Dermal, subcutaneous, and tendon xanthomas: diagnostic markers for specific lipoprotein disorders. J Am Acad Dermatol 1988; 19:95.</a></li><li><a class="nounderline abstract_t">Parker F. Normocholesterolemic xanthomatosis. Arch Dermatol 1986; 122:1253.</a></li><li><a class="nounderline abstract_t">Parker F, Bagdade JD, Odland GF, Bierman EL. Evidence for the chylomicron origin of lipids accumulating in diabetic eruptive xanthomas: a correlative lipid biochemical, histochemical, and electron microscopic study. J Clin Invest 1970; 49:2172.</a></li><li><a class="nounderline abstract_t">Wilson JD. Studies on the origin of the lipid components of xanthomata. Circ Res 1963; 12:472.</a></li><li><a class="nounderline abstract_t">Hu CH, Ellefson RD, Winkelmann RK. Lipid synthesis in cutaneous xanthoma. J Invest Dermatol 1982; 79:80.</a></li><li><a class="nounderline abstract_t">Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983; 67:968.</a></li><li><a class="nounderline abstract_t">Smellie WS. Hypertriglyceridaemia in diabetes. BMJ 2006; 333:1257.</a></li><li><a class="nounderline abstract_t">Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis 1994; 23:331.</a></li><li><a class="nounderline abstract_t">Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39:169.</a></li><li><a class="nounderline abstract_t">O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993; 68:860.</a></li><li><a class="nounderline abstract_t">Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325:1196.</a></li><li><a class="nounderline abstract_t">Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992; 166:950.</a></li><li><a class="nounderline abstract_t">Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133.</a></li><li><a class="nounderline abstract_t">Hilbrands LB, Demacker PN, Hoitsma AJ, et al. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995; 5:2073.</a></li><li><a class="nounderline abstract_t">Klör HU, Weizel A, Augustin M, et al. The impact of oral vitamin A derivatives on lipid metabolism - What recommendations can be derived for dealing with this issue in the daily dermatological practice? J Dtsch Dermatol Ges 2011; 9:600.</a></li><li><a class="nounderline abstract_t">Sayin I, Ayli M, Oğuz AK, Seval GC. Xanthelasma palpebrarum: a new side effect of nilotinib. BMJ Case Rep 2016; 2016.</a></li><li><a class="nounderline abstract_t">Szalat R, Arnulf B, Karlin L, et al. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. Blood 2011; 118:3777.</a></li><li><a class="nounderline abstract_t">Hegde U, Doddawad VG, Sreeshyla H, Patil R. Verruciform xanthoma: A view on the concepts of its etiopathogenesis. J Oral Maxillofac Pathol 2013; 17:392.</a></li><li class="breakAll">Cutaneous infiltrates - Non-lymphoid. In: Weedon's Skin Pathology, 4th ed, Patterson JW, Hosler GA, Weedon D (Eds), Churchill Livingstone Elsevier, 2015. p.1129.</li><li><a class="nounderline abstract_t">Ravić-Nikolić A, Mladenović V, Mitrović S, et al. Generalized eruptive xanthomas associated with diabetic dyslipidemia. Eur J Dermatol 2014; 24:394.</a></li><li><a class="nounderline abstract_t">Solak B, Kara RO, Acikgoz SB, Kosem M. First and only symptom of undiagnosed diabetes mellitus: eruptive xanthoma. BMJ Case Rep 2015; 2015.</a></li><li><a class="nounderline abstract_t">Bounouar M, Mernissi F. [Eruptive xanthomas announcing severe acute pancreatitis]. Pan Afr Med J 2014; 17:225.</a></li><li><a class="nounderline abstract_t">Moghadasian MH. Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds. Clin Invest Med 2004; 27:42.</a></li><li><a class="nounderline abstract_t">Bhattacharyya AK, Connor WE. Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters. J Clin Invest 1974; 53:1033.</a></li><li><a class="nounderline abstract_t">Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012; 223:262.</a></li><li><a class="nounderline abstract_t">Sil A, Bhanja DB, Biswas SK. Intertriginous Xanthomas-Pathognomonic Cutaneous Markers of Homozygous Familial Hypercholesterolemia. JAMA Dermatol 2021; 157:1228.</a></li><li><a class="nounderline abstract_t">Baila-Rueda L, Mateo-Gallego R, Lamiquiz-Moneo I, et al. Severe hypercholesterolemia and phytosterolemia with extensive xanthomas in primary biliary cirrhosis: role of biliary excretion on sterol homeostasis. J Clin Lipidol 2014; 8:520.</a></li><li><a class="nounderline abstract_t">Macías-Rodríguez RU, Torre-Delgadillo A. Xanthelasmas and xanthomatas striatum palmare in primary biliary cirrhosis. Ann Hepatol 2006; 5:49.</a></li><li><a class="nounderline abstract_t">Weston CF, Burton JL. Xanthomas in the Watson-Alagille syndrome. J Am Acad Dermatol 1987; 16:1117.</a></li><li><a class="nounderline abstract_t">Chang HC, Sung CW, Lin MH. Serum lipids and risk of atherosclerosis in xanthelasma palpebrarum: A systematic review and meta-analysis. J Am Acad Dermatol 2020; 82:596.</a></li><li><a class="nounderline abstract_t">Lynch MC, Wood L, Anderson BE, Clarke LE. JAAD Grand Rounds. Asymptomatic dermal plaques. J Am Acad Dermatol 2015; 72:922.</a></li><li><a class="nounderline abstract_t">Marcoval J, Moreno A, Bordas X, et al. Diffuse plane xanthoma: clinicopathologic study of 8 cases. J Am Acad Dermatol 1998; 39:439.</a></li><li><a class="nounderline abstract_t">Blankenship DW, Zech L, Mirzabeigi M, Venna S. Verruciform xanthoma of the upper-extremity in the absence of chronic skin disease or syndrome: a case report and review of the literature. J Cutan Pathol 2013; 40:745.</a></li><li><a class="nounderline abstract_t">Curto-Barredo L, Segura S, Barranco C, et al. Verruciform xanthoma developing in recessive dystrophic epidermolysis bullosa: A sheep in wolf's clothing. Am J Dermatopathol 2014; 36:506.</a></li><li><a class="nounderline abstract_t">Xu XL, Huang LM, Wang Q, Sun JF. Multiple verruciform xanthomas in the setting of congenital hemidysplasia with ichthyosiform erythroderma and limb defects syndrome. Pediatr Dermatol 2015; 32:135.</a></li><li><a class="nounderline abstract_t">Chyu J, Medenica M, Whitney DH. Verruciform xanthoma of the lower extremity--report of a case and review of literature. J Am Acad Dermatol 1987; 17:695.</a></li><li><a class="nounderline abstract_t">Huguet P, Toran N, Tarragona J. Cutaneous verruciform xanthoma arising on a congenital lymphoedematous leg. Histopathology 1995; 26:277.</a></li><li><a class="nounderline abstract_t">Romaní J, Luelmo J, Sáez A, et al. Localized xanthomas associated with primary lymphedema. Pediatr Dermatol 2012; 29:113.</a></li><li><a class="nounderline abstract_t">Mannes KD, Dekle CL, Requena L, Sangueza OP. Verruciform xanthoma associated with squamous cell carcinoma. Am J Dermatopathol 1999; 21:66.</a></li><li><a class="nounderline abstract_t">Shahrabi Farahani S, Treister NS, Khan Z, Woo SB. Oral verruciform xanthoma associated with chronic graft-versus-host disease: a report of five cases and a review of the literature. Head Neck Pathol 2011; 5:193.</a></li><li><a class="nounderline abstract_t">Polonowita AD, Firth NA, Rich AM. Verruciform xanthoma and concomitant lichen planus of the oral mucosa. A report of three cases. Int J Oral Maxillofac Surg 1999; 28:62.</a></li><li><a class="nounderline abstract_t">Miyamoto Y, Nagayama M, Hayashi Y. Verruciform xanthoma occurring within oral lichen planus. J Oral Pathol Med 1996; 25:188.</a></li><li><a class="nounderline abstract_t">Harris L, Staines K, Pring M. Oral verruciform xanthoma. BMJ Case Rep 2015; 2015.</a></li><li><a class="nounderline abstract_t">Gong HZ, Zheng HY, Li J. Xanthoma disseminatum. Lancet 2018; 391:251.</a></li><li><a class="nounderline abstract_t">Yamamoto A, Matsuzawa Y, Yokoyama S, et al. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986; 57:29H.</a></li><li><a class="nounderline abstract_t">Fujita M, Shirai K. A comparative study of the therapeutic effect of probucol and pravastatin on xanthelasma. J Dermatol 1996; 23:598.</a></li><li><a class="nounderline abstract_t">Inazu A, Koizumi J, Kajinami K, et al. Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. Atherosclerosis 1999; 145:405.</a></li><li><a class="nounderline abstract_t">Lee HY, Jin US, Minn KW, Park YO. Outcomes of surgical management of xanthelasma palpebrarum. Arch Plast Surg 2013; 40:380.</a></li><li><a class="nounderline abstract_t">Mourad B, Elgarhy LH, Ellakkawy HA, Elmahdy N. Assessment of efficacy and tolerability of different concentrations of trichloroacetic acid vs. carbon dioxide laser in treatment of xanthelasma palpebrarum. J Cosmet Dermatol 2015; 14:209.</a></li><li><a class="nounderline abstract_t">Esmat SM, Elramly AZ, Abdel Halim DM, et al. Fractional CO2 laser is an effective therapeutic modality for xanthelasma palpebrarum: a randomized clinical trial. Dermatol Surg 2014; 40:1349.</a></li><li><a class="nounderline abstract_t">Güngör S, Canat D, Gökdemir G. Erbium: YAG laser ablation versus 70% trichloroacetıc acid application in the treatment of xanthelasma palpebrarum. J Dermatolog Treat 2014; 25:290.</a></li><li><a class="nounderline abstract_t">Labandeira J, Vázquez-Osorio I, Figueroa-Silva O, et al. Tolerability and effectiveness of liquid nitrogen spray cryotherapy with very short freeze times in the treatment of xanthelasma palpebrarum. Dermatol Ther 2015; 28:346.</a></li><li><a class="nounderline abstract_t">Heng JK, Chua SH, Goh CL, et al. Treatment of xanthelasma palpebrarum with a 1064-nm, Q-switched Nd:YAG laser. J Am Acad Dermatol 2017; 77:728.</a></li><li><a class="nounderline abstract_t">Lin X, Hu H, Qian Y, et al. Intralesional injection of bleomycin in the treatment of xanthelasma palpebrarum: A clinical study. J Cosmet Dermatol 2020; 19:2125.</a></li><li><a class="nounderline abstract_t">Tuan H, Chen Y, Yang S, et al. A Comparison of Efficacy and Safety of Fractional Carbon Dioxide Laser and Fractional Er:YAG Laser for the Treatment of Xanthelasma Palpebrarum: A Two-Center Randomized Split-Face Controlled Trial. Photobiomodul Photomed Laser Surg 2021; 39:131.</a></li><li><a class="nounderline abstract_t">Guo Y, Dang Y, Toyohara JP, Geng S. Successful treatment of verruciform xanthoma with imiquimod. J Am Acad Dermatol 2013; 69:e184.</a></li><li><a class="nounderline abstract_t">Connolly SB, Lewis EJ, Lindholm JS, et al. Management of cutaneous verruciform xanthoma. J Am Acad Dermatol 2000; 42:343.</a></li><li><a class="nounderline abstract_t">Mohsin SK, Lee MW, Amin MB, et al. Cutaneous verruciform xanthoma: a report of five cases investigating the etiology and nature of xanthomatous cells. Am J Surg Pathol 1998; 22:479.</a></li><li><a class="nounderline abstract_t">Joo J, Fung MA, Jagdeo J. Successful treatment of scrotal verruciform xanthoma with shave debulking and fractionated carbon dioxide laser therapy. Dermatol Surg 2014; 40:214.</a></li><li><a class="nounderline abstract_t">Esmat S, Abdel-Halim MR, Fawzy MM, et al. Are normolipidaemic patients with xanthelasma prone to atherosclerosis? Clin Exp Dermatol 2015; 40:373.</a></li></ol></div><div id="topicVersionRevision">Topic 13786 Version 10.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24781043" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Xanthomas: clinical and pathophysiological relations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/657837" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Xanthomas and lipoproteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3042820" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Dermal, subcutaneous, and tendon xanthomas: diagnostic markers for specific lipoprotein disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3096220" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Normocholesterolemic xanthomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5480845" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evidence for the chylomicron origin of lipids accumulating in diabetic eruptive xanthomas: a correlative lipid biochemical, histochemical, and electron microscopic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Studies on the origin of the lipid components of xanthomata</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7097039" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lipid synthesis in cutaneous xanthoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6219830" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17170417" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hypertriglyceridaemia in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8128933" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2002630" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lipid abnormalities in renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8371604" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hyperlipidemia in patients with primary and secondary hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1922206" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1550171" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7992988" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effects of antihypertensive therapy on serum lipids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579056" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21392258" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The impact of oral vitamin A derivatives on lipid metabolism - What recommendations can be derived for dealing with this issue in the daily dermatological practice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26759444" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Xanthelasma palpebrarum: a new side effect of nilotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21757618" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24574658" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Verruciform xanthoma: A view on the concepts of its etiopathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24574658" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Verruciform xanthoma: A view on the concepts of its etiopathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24721907" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Generalized eruptive xanthomas associated with diabetic dyslipidemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26404550" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : First and only symptom of undiagnosed diabetes mellitus: eruptive xanthoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25170369" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : [Eruptive xanthomas announcing severe acute pancreatitis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15061585" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4360855" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22398274" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34468693" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Intertriginous Xanthomas-Pathognomonic Cutaneous Markers of Homozygous Familial Hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25234565" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Severe hypercholesterolemia and phytosterolemia with extensive xanthomas in primary biliary cirrhosis: role of biliary excretion on sterol homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16531966" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Xanthelasmas and xanthomatas striatum palmare in primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3108338" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Xanthomas in the Watson-Alagille syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31499151" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Serum lipids and risk of atherosclerosis in xanthelasma palpebrarum: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25890466" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : JAAD Grand Rounds. Asymptomatic dermal plaques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9738779" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Diffuse plane xanthoma: clinicopathologic study of 8 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23656213" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Verruciform xanthoma of the upper-extremity in the absence of chronic skin disease or syndrome: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23676320" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Verruciform xanthoma developing in recessive dystrophic epidermolysis bullosa: A sheep in wolf's clothing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24147604" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Multiple verruciform xanthomas in the setting of congenital hemidysplasia with ichthyosiform erythroderma and limb defects syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3312319" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Verruciform xanthoma of the lower extremity--report of a case and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7797206" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cutaneous verruciform xanthoma arising on a congenital lymphoedematous leg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22256994" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Localized xanthomas associated with primary lymphedema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027531" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Verruciform xanthoma associated with squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21305367" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Oral verruciform xanthoma associated with chronic graft-versus-host disease: a report of five cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10065655" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Verruciform xanthoma and concomitant lichen planus of the oral mucosa. A report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8809688" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Verruciform xanthoma occurring within oral lichen planus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25819830" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Oral verruciform xanthoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29031846" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Xanthoma disseminatum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3728307" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effects of probucol on xanthomata regression in familial hypercholesterolemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8916658" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A comparative study of the therapeutic effect of probucol and pravastatin on xanthelasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10488970" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23898435" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Outcomes of surgical management of xanthelasma palpebrarum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26251333" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Assessment of efficacy and tolerability of different concentrations of trichloroacetic acid vs. carbon dioxide laser in treatment of xanthelasma palpebrarum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25380092" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fractional CO2 laser is an effective therapeutic modality for xanthelasma palpebrarum: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23441855" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Erbium: YAG laser ablation versus 70% trichloroacetıc acid application in the treatment of xanthelasma palpebrarum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26088022" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Tolerability and effectiveness of liquid nitrogen spray cryotherapy with very short freeze times in the treatment of xanthelasma palpebrarum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28666611" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment of xanthelasma palpebrarum with a 1064-nm, Q-switched Nd:YAG laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31930760" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intralesional injection of bleomycin in the treatment of xanthelasma palpebrarum: A clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33449843" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A Comparison of Efficacy and Safety of Fractional Carbon Dioxide Laser and Fractional Er:YAG Laser for the Treatment of Xanthelasma Palpebrarum: A Two-Center Randomized Split-Face Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24034392" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Successful treatment of verruciform xanthoma with imiquimod.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10640929" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Management of cutaneous verruciform xanthoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9537477" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cutaneous verruciform xanthoma: a report of five cases investigating the etiology and nature of xanthomatous cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24320039" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Successful treatment of scrotal verruciform xanthoma with shave debulking and fractionated carbon dioxide laser therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25683563" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Are normolipidaemic patients with xanthelasma prone to atherosclerosis?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
